BioSpace News Archive

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced it has signed an exclusive global distribution agreement with ADS Biotec for the sale and distribution of its proprietary IV-Cell cytogenetics cell culturing media.

Self-collected saliva and deep nasal swabs collected by healthcare providers are equally effective for detecting SARS-CoV-2, the virus that causes COVID-19, according to a new study conducted by ARUP Laboratories and University of Utah (U of U) Health.

NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell device will be used in an NIH-funded, multi-site randomized controlled trial (RCT) of the efficacy of transcutaneous electrical nerve stimulation (TENS) for chemotherapy-induced peripheral neuropathy (CIPN).

“AACC welcomes a decision from the Department of Health and Human Services that the Food and Drug Administration does not have authority to regulate laboratory developed tests (LDTs) without formal notice-and-comment rulemaking.

In celebration of Childhood Cancer Awareness Month, supporters of St. Jude Children’s Research Hospital® are lacing up their shoes to walk, run and fundraise at their own pace and distance in neighborhoods across the country for the annual St. Jude Walk/Run on Saturday, Sept. 26.

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has completed its investigation regarding a report of discordant results (False Positives) at a testing location in Vermont,

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and infusible drug formulations, today announced that its Board of Directors has promoted John P. Shannon to the position of President and Chief Operating Officer, effective immediately. In his new role, Mr. Shannon will be responsible for

TechnoVax, Inc, a biotechnology developer of novel vaccines and The CUNY School of Medicine at The City College of New York, announce a breakthrough in their collaborative effort to develop a vaccine for COVID-19.

Atrion Corporation announced an increase in its quarterly cash dividend from $1.55 per share to $1.75 per share. Specifically, the Board of Directors declared a quarterly dividend of $1.75 per share on its outstanding shares of Common Stock.

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 270,000 shares of Geron common stock as inducements to four newly-hired employees in connection with commencement of employment with the Company.